New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 3: Heavily Pretreated Multiple Myeloma and Drugs in Development

Please Log In or Register to continue.

Release Date: August 18, 2020
Expiration Date: August 18, 2021

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will focus on heavily pretreated multiple myeloma and drugs in development. Through the case of Carl, a patient who has received several multiple myeloma therapies over his 10-year history with the disease, our faculty will discuss clinical trial participation, and drugs in development. Please remember to complete part 1 and 2 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.

Target Audience

This activity is designed for nurses and other medical personnel involved in care of patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify common treatment regimens in newly diagnosed and relapsed multiple myeloma
  • Discuss nursing management of MM patients receiving myeloma therapeutic regimens, including effective symptom management
  • Discuss the importance of survivorship care plans and practical tools for long-term management and care of MM patients
  • Discuss timely recommendations for infection control among an immunocompromised patient population

Agenda

Heavily Pretreated Multiple Myeloma and Drugs in Development

  1. Common treatment regiments in heavily pretreated multiple myeloma
  2. Drugs currently in clinical trial
  3. Nursing management, including symptom management
  4. One case study:
    • Carl – a 10-year survivor experiencing a symptomatic relapse

Instructions for Participation and Credit

This activity is eligible for credit through August 18, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You will be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 100%. You will be able to review the correct answers along with the rationale before completing the program. Please note you must achieve a passing score within 3 attempts or you will be unable to complete the activity and earn CNE credit.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
  7. Your online certificate will be saved on ManagingMyeloma.com in your CE Records, which you can access at any time using your login.

Faculty Biographies

Beth Faiman, PhD

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN
Adult Nurse Practitioner
Multiple Myeloma Program
Hematology/Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Dr. Beth Faiman received a Bachelor of Science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a Master of Science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio. She is adjunct faculty at Ursuline College, Case Western Reserve University, and Kent State University. Dr. Faiman is the recipient of a many awards including the 2012 Excellence in Medical Oncology, the 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society, and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University. She was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. Additionally, Dr. Faiman was recognized by ONS for her contributions to healthcare through selection to the American Academy of Nursing in 2019, and the American Board of Internal Medicine (ABIM) appointed Dr. Beth Faiman to ABIM Hematology Specialty Board in July. The ABIM is responsible for governing the licensure of current and future board-certified hem/onc physicians.

Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, amyloidosis, chronic leukemia, plasma cell dyscrasias, and general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is currently Editor-in-Chief of The Oncology Nurse APN/PA and on the editorial board of ASH Clinical News among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman has served as a prolific speaker, publisher, and committee leader conducting original research for over thirteen years as a distinguished member of the International Myeloma Foundation Nurse Leadership Board.

Tiffany Richards, PhD


Tiffany Richards, PhD, ANP-BC, AOCNP®
MD Anderson Cancer Center
Houston, TX

Tiffany Richards, PhD, ANP-BC, AOCNP® received her bachelor’s degree in Nursing, as well as her master’s degree from the University of Wisconsin-Madison. She earned a PhD in Nursing at the Texas Woman’s University. Dr. Richards is presently employed as an Adult Nurse Practitioner at the MD Anderson Cancer Center where she is the supervisor of the Myeloma Advanced Practice Providers. Dr. Richards holds certifications as an Adult Nurse Practitioner, as well as an Advanced Oncology Certified Nurse Practitioner.

Dr. Richards volunteers her time in the community, serving as co-facilitator of a local multiple myeloma support group for the past twelve years. She is an active member of the Oncology Nursing Society. Dr. Richards is the recipient of numerous awards including MD Anderson’s 2008 Excellence in Advanced Practice Nursing, Texas Nurses Association-Houston Chapter Top 20 Nurses for 2008 Award, 2008 South Central Nurse Excellence Award Finalist, Oncology Nursing Society Excellence in Public/Patient Education, and the MD Anderson 2013 Division of Medicine Exemplary Employee Award.

Dr. Richards has spoken widely on subjects related to multiple myeloma including symptom management of patients with multiple myeloma. Her primary research interest includes targeted therapies for patients with multiple myeloma. Dr. Richards publications in multiple myeloma include a chapter entitled: “Nursing Research” in Multiple Myeloma: A Textbook for Nurses (2nd ed.), as well as articles in CJON, JADPRO, and Multidisciplinary Cancer Care. Dr. Richards has been a distinguished member of the International Myeloma Foundation Nursing Leadership Board (NLB) since 2007, serving on the board to help educate nurses and patients and to improve the lives of those with myeloma.

Accreditation

Nursing Continuing Education
Accreditation Statement: Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement: 0.5 contact hours may be earned for successful completion of this activity. A total of 1.5 contact hours may be earned by completing all 3 activities in this course.

Faculty Disclosures

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CNE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Name of Faculty

Reported Financial Relationship

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN

Consulting fee from Celgene/BMS, GSK, Karyopharm

Tiffany Richards, PhD, ANP-BC, AOCNP®

Honoraria from Celgene, GSK, Takeda

Accreditor Disclosures

The content and program managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Content or Program Manager

Reported Financial Relationship

Annenberg Center for Health Sciences at Eisenhower

None to disclose

Joyce Divine, PhD, MBA

Employment by the Lockwood Group

Michelle Faber, MS

None to disclose

Diane Moran, RN, MA, EdM

None to disclose

Maya Ormsby, MS, MBA, MIM

None to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

ONS Disclaimer

A presentation timeslot has been assigned to provide a symposium supported by the International Myeloma Foundation during the Oncology Nursing Society’s (ONS) Bridge Virtual Event. The Oncology Nursing Society's assignment of a presentation timeslot does not imply product endorsement. 

Provided by the International Myeloma Foundation

Accredited by Annenberg Center for Health Sciences at Eisenhower

Supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology.

 

©2020 International Myeloma Foundation, 12650 Riverside Drive, Suite 206, North Hollywood, CA 91607, USA, Tel: 1-818-487-7455

No portion of this material may be copied or duplicated without the expressed permission of the International Myeloma Foundation.

Please Log In or Register to continue.